FDA approves updated prescribing information for Tradjenta® (linagliptin) tablets for add-on therapy to insulin in adults with type 2 diabetes
10:58 EDT 17 Aug 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 17, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug applica...
Other Sources for this Article
More From BioPortfolio on "FDA approves updated prescribing information for Tradjenta® (linagliptin) tablets for add-on therapy to insulin in adults with type 2 diabetes"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
